A Cholesterol Drug Fail To Perform Well. On Monday, drug maker Eli Lilly announced that it was ceasing work on a new cholesterol-lowering drug, after the drug failed to perform well in a phase 3 clinical trial. The drug, evacetrapib, was designed to prevent heart attacks and other cardiovascular problems by modifying cholesterol … [Read more...]
Eli Lilly Abandons Development of New Cholesterol Drug after Poor Performance in Phase 3 Trial
Eli Lilly Abandons Development of New Cholesterol Drug
Eli Lilly Ceased Work For New Cholesterol Drug. Drug maker Eli Lilly announced that it was ceasing work on a new cholesterol-lowering drug, after the drug failed to perform well in a phase 3 clinical trial. The drug, evacetrapib, was designed to prevent heart attacks and other cardiovascular problems by modifying cholesterol … [Read more...]
Philippine FDA Announces Two Drug Recalls
The Philippine FDA Two Drug Recalls. The Food and Drug Administration (FDA) of the Philippines, in two separate advisories, has recalled specific lots and batches of two drug products: a cholesterol-lowering drug, and a drug used in the treatment of tuberculosis and other infections. In its advisories, the Philippine regulatory … [Read more...]
Vytorin Probe Seeks Information
Vytorin Probe Seeks Information. Lawmakers investigating the cholesterol drug Vytorin have asked Merck and Schering-Plough for more information on the medication's clinical trials. According to Reuters, Rep. Henry Waxman (D-Calif), chairman of the House Energy and Commerce Committee, has written two companies on Thursday seeking … [Read more...]
Vytorin Confusion Leaves Patients Wondering
Vytorin Confusion Leaves Patients Wondering. Many patients - and probably some doctors - are scratching their heads over Vytorin. Though it has been on the market for four years, little is known about its safety and effectiveness. This year, two studies - ENHANCE and SEAS - have only added to the confusion over the cholesterol … [Read more...]
Another Vytorin Failure
Another Vytorin Failure. Yesterday's news that Vytorin failed to meet the primary endpoint in another important study has not done much to restore faith in the controversial cholesterol drug. First shown to be ineffective in preventing clogged arteries, it now seems Vytorin does little to help patients with aortic stenosis avoid … [Read more...]
Call for Withdrawal of Cholesterol Drug
Cholesterol Drug Crestor Can Cause Kidney Damage. A leading consumer watchdog group issued a new warning Friday about the cholesterol-lowering drug Crestor, alleging that patients who use it are 75 times likelier to suffer kidney damage than are patients using any other statin. Public Citizen has been urging the U.S. Food and Drug … [Read more...]
